Hypermethylation of OPRM1: Deregulation of the Endogenous Opioid Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia. — CFSMEATLAS
Hypermethylation of OPRM1: Deregulation of the Endogenous Opioid Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia.
Wyns, Arne, Hendrix, Jolien, Van Campenhout, Jente et al. · International journal of molecular sciences · 2026 · DOI
Quick Summary
This study examined whether changes in how a gene called OPRM1 (which controls opioid receptors in the body) are chemically marked in people with ME/CFS and fibromyalgia. Researchers found that people with these conditions had higher levels of these chemical marks on the OPRM1 gene compared to healthy people, even after accounting for how severe their symptoms were. This suggests that problems with the body's natural pain-relief system may be a fundamental part of these illnesses.
Why It Matters
This is the first study to identify epigenetic modifications of the opioid receptor gene in ME/CFS and fibromyalgia, providing potential biological evidence for abnormalities in natural pain-modulation systems that could explain why these patients experience disproportionate pain and fatigue. Understanding this mechanism may eventually lead to new diagnostic tools and targeted treatments for these poorly understood conditions.
OPRM1 methylation elevation persisted after adjusting for symptom severity and pain sensitivity measures
OPRM1 methylation correlated with BDNF promoter methylation at both study visits
No significant differences in global DNA methylation levels were found between patients and controls
Patients reported significantly worse chronic pain, fatigue, and other clinical symptoms on validated questionnaires
Inferred Conclusions
Dysregulation of opioidergic signaling via epigenetic OPRM1 modifications may be a fundamental pathophysiological mechanism in ME/CFS and fibromyalgia
OPRM1 methylation changes appear independent of current symptom severity, suggesting they may reflect a primary biological abnormality rather than a secondary effect of illness
The correlation between OPRM1 and BDNF methylation suggests interconnected dysregulation of pain and neuroplasticity pathways in these conditions
Remaining Questions
Does OPRM1 hypermethylation actually reduce mu-opioid receptor expression and function, and if so, by how much?
Are these methylation patterns present at disease onset, or do they develop over time, and can they be reversed with treatment?
What This Study Does Not Prove
This study does not prove that increased OPRM1 methylation causes ME/CFS or fibromyalgia, only that an association exists. It also does not demonstrate that this methylation actually reduces opioid receptor function or activity—only that the chemical modification is present. Finally, because methylation patterns were measured at single timepoints, the study cannot determine whether these changes are stable, develop before symptom onset, or represent a consequence of disease.
Tags
Symptom:PainFatigue
Biomarker:Gene Expression
Method Flag:PEM Not DefinedSmall SampleExploratory OnlyMixed Cohort
Why are some individuals with these methylation changes symptomatic while potentially others are not, and what additional genetic or environmental factors modify disease expression?
Could OPRM1 methylation status serve as a biomarker for diagnosis or prognosis, and do methylation levels correlate with treatment response?